Works matching IS 01676997 AND DT 2009 AND VI 27 AND IP 2

Results: 14

Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

Published in:

2009

By:

Schilling G;
Bruweleit M;
Harbeck N;
Thomssen C;
Becker K;
Hoffmann R;
Villena C;
Schütte M;
Hossfeld DK;
Bokemeyer C;
de Wit M

Publication type:

Journal Article

In vitro cytotoxic activity of tri-n-butyltin(IV)lupinylsulfide hydrogen fumarate (IST-FS 35) and preliminary antitumor activity in vivo.

Published in:

2009

By:

Alama A;
Viale M;
Cilli M;
Bruzzo C;
Novelli F;
Tasso B;
Sparatore F

Publication type:

Journal Article

Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy).

Published in:

Investigational New Drugs, 2009, v. 27, n. 2, p. 166, doi. 10.1007/s10637-008-9166-8

By:

Schilling, G.;
Bruweleit, M.;
Harbeck, N.;
Thomssen, C.;
Becker, K.;
Hoffmann, R.;
Villena, C.;
Schütte, M.;
Hossfeld, D.;
Bokemeyer, C.;
Wit, M.

Publication type:

Article

Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R).

Published in:

Investigational New Drugs, 2009, v. 27, n. 2, p. 99, doi. 10.1007/s10637-008-9140-5

By:

Pešić, Milica;
Andjelković, Tijana;
Banković, Jasna;
Marković, Ivanka;
Rakić, Ljubiša;
Ruždijić, Sabera

Publication type:

Article

Synthesis and antiproliferative activity of substituted diazaspiro hydantoins: a structure–activity relationship study.

Published in:

Investigational New Drugs, 2009, v. 27, n. 2, p. 131, doi. 10.1007/s10637-008-9150-3

By:

C. S., Ananda;
Prasad, S.;
Vinaya, K.;
Chandrappa, S.;
Thimmegowda, N.;
Ranganatha, S.;
Swarup, Sanjay;
Rangappa, K.

Publication type:

Article

Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.

Published in:

Investigational New Drugs, 2009, v. 27, n. 2, p. 153, doi. 10.1007/s10637-008-9172-x

By:

Sayar, H.;
Shen, Z.;
Lee, S.;
Royce, M.;
Rabinowitz, I.;
Lee, F.;
Smith, H.;
Eberhardt, S.;
Maestas, A.;
Lu, H.;
Verschraegen, C.

Publication type:

Article

Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients.

Published in:

2009

By:

Al-Dasooqi, Noor;
Bowen, Joanne;
Gibson, Rachel;
Sullivan, Thomas;
Lees, Jude;
Keefe, Dorothy

Publication type:

Report

In vitro cytotoxic activity of tri- n-butyltin(IV)lupinylsulfide hydrogen fumarate (IST-FS 35) and preliminary antitumor activity in vivo.

Published in:

Investigational New Drugs, 2009, v. 27, n. 2, p. 124, doi. 10.1007/s10637-008-9148-x

By:

Alama, Angela;
Viale, Maurizio;
Cilli, Michele;
Bruzzo, Cristina;
Novelli, Federica;
Tasso, Bruno;
Sparatore, Fabio

Publication type:

Article

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer.

Published in:

2009

By:

Gullo, Giuseppe;
Bettio, Daniela;
Torri, Valter;
Masci, Giovanna;
Salvini, Piermario;
Santoro, Armando

Publication type:

Report

Suppressive effects of novel derivatives prepared from Aconitum alkaloids on tumor growth.

Published in:

Investigational New Drugs, 2009, v. 27, n. 2, p. 111, doi. 10.1007/s10637-008-9141-4

By:

Hazawa, Masaharu;
Wada, Koji;
Takahashi, Kenji;
Mori, Takao;
Kawahara, Norio;
Kashiwakura, Ikuo

Publication type:

Article

Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer.

Published in:

Investigational New Drugs, 2009, v. 27, n. 2, p. 120, doi. 10.1007/s10637-008-9145-0

By:

Buijs, Manon;
Vossen, Josephina;
Geschwind, Jean-Francois;
Ishimori, Takayoshi;
Engles, James;
Acha-Ngwodo, Obele;
Wahl, Richard;
Vali, Mustafa

Publication type:

Article

Bowel perforation in non-small cell lung cancer after bevacizumab therapy.

Published in:

2009

By:

Schellhaas, Elisabeth;
Loddenkemper, Christoph;
Schmittel, Alexander;
Buhr, Heinz-J.;
Pohlen, Uwe

Publication type:

Report

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.

Published in:

Investigational New Drugs, 2009, v. 27, n. 2, p. 140, doi. 10.1007/s10637-008-9164-x

By:

Keizer, Ron;
Zamacona, Miren;
Jansen, Mendel;
Critchley, David;
Wanders, Jantien;
Beijnen, Jos;
Schellens, Jan;
Huitema, Alwin

Publication type:

Article

A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2009, v. 27, n. 2, p. 159, doi. 10.1007/s10637-008-9165-9

By:

Gartner, Elaina;
Griffith, Kent;
Pan, Quintin;
Brewer, George;
Henja, Gwen;
Merajver, Sofia;
Zalupski, Mark

Publication type:

Article